|
|
Article: Report summarizes leukemia therapy study findings from Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Article from:
- Blood Weekly
- Article date:
- November 6, 2008
CopyrightCOPYRIGHT 2008 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A report, 'Targeting FLT3 for the Treatment of Leukemia,' is newly published data in Seminars In Hematology. "FLT3 is a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell survival and proliferation. It is frequently overexpressed in acute leukemias and is frequently mutated in acute myeloid leukemia (AML)," researchers in the United States report (see also Leukemia Therapy).
"FLT3 internal tandem duplication (ITD) mutations in AML portend poor prognosis in both adult and pediatric patients. A number of small molecule tyrosine kinase inhibitors (TKIs) with activity against FLT3 have been discovered. Many of these are still in ...
Related newspaper, magazine, and journal articles:
|
|
Article: Commission on Cancer of the American College of Surgeons ...
Cancer Weekly;
May 26, 2009 ;
700+ words
... ... the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview with ... The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview includes ... the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview ...
|
|